References
- Saag KG, Teng GG, Patkar N, Anuntiyo J, Finney C, Curtis JR, . American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762–84.
- British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF treatment. Thorax 2005;60:800–5.
- Belknap R, Reves R, Burman W. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. Int J Tuberc Lung Dis 2005;9:1057–60.
- Lawn SD, Wilkinson RJ, Lipman MCI, Wood R. Immune reconstitution and ‘unmasking’ of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008;177:680–5.
- Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life threatening tuberculosis. Clin Infect Dis 2009;48:1429–32.
- Garcia Vidal C, Rodriguez Fernandez S, Martinez Lacasa J, Salavert M, Vidal R, Rodriguez Carballeira M, . Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005;40:756–9.
- Vlachaki E, Psathakis K, Tsintiris K, Iliopoulos A. Delayed response to anti-tuberculosis treatment in a patient on infliximab. Respir Med 2005;99:648–52.
- Arend SM, Leyten EM, Franken WP, Huisman EM, van Dissel JT. A patient with de novo tuberculosis during anti-tumor necrosis factor: a therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 2007;45:1470–5.
- Winthrop KL, Yamashita S, Beekmann SE, Polgreen PM; Infectious Diseases Society of America Emerging Infections Network. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008;46:1738–40.